



Join us by the beach at our Spring ROTH Conference for panels on three hot topics of healthcare

Monday, March 18, 2019 and Tuesday, March 19, 2019

Jotin Marango, MD, PhD, ROTH Senior Research Analyst and Managing Director, is pleased to invite you to our 31st Annual ROTH Conference on March 17-19. Our three topical panel discussions will explore key issues of the **development, regulatory, and commercial landscape in hematology/oncology and neurodegeneration.**

Monday, March 18	
2:00pm-03:00pm	<p>Alzheimer's Disease: Beyond the Rise and Fall of Amyloid Participants: Adam Rosenberg, CEO, Rodin Therapeutics (private); Christopher Missling, PhD, CEO, Anavex Life Sciences (AVXL); Michael Ropacki, MD; VP of CNS Development, Oryzon Genomics (ORY.SM)</p>
3:00am-4:00pm	<p>The Brave New World Of Myeloid Tumors Participants: Helen Thackray, MD, CMO, GlycoMimetics (GLYC); Ivan Bergstein, MD, CEO, Stemline Therapeutics (STML); Mark Berger, MD, CMO, Actinium (ATNM); Steven Fruchtman, MD, CEO, Onconova Therapeutics (ONTX)</p>
Tuesday, March 19	
8:30am-9:30am	<p>New BTK Drugs on the Block Participants: Judith Fox, MD, CSO, Sunesis Pharmaceuticals (SNSS); Paolo Pucci, CEO, ArQule (ARQL); William Rice, PhD, CEO, Aptose Biosciences (APTO)</p>

This event is by invitation only. Please email registration@roth.com or contact your ROTH representative at 800.933.6830.